TECH · XBRL financial data

BIO-TECHNE financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TECH's year ends in late June)

In millions of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Revenue	—	—	1,137	1,159	1,220	1,215
Revenue from contracts with customers	931	1,106	1,137	1,159	1,220	1,215
Cost of goods and services sold	298	349	367	389	429	416
Gross profit	633	756	770	770	790	799
Selling, general and administrative	325	373	378	466	589	452
Total operating expenses	396	460	471	563	688	547
Operating income (loss)	237	297	299	207	102	252
Interest expense	14	11	11	16	9	10
Other income (expense)	(76)	15	48	(9)	1	(6)
Income tax expense (benefit)	9	38	53	18	25	59
Net income (loss)	140	272	285	168	73	—
Earnings per share, basic‡ USD per share	0.91	1.73	1.81	1.07	0.47	1.17
Earnings per share, diluted‡ USD per share	0.87	1.66	1.76	1.05	0.46	1.16
Weighted average shares, basic‡ millions of shares	155	157	157	158	158	156
Weighted average shares, diluted‡ millions of shares	162	164	162	161	160	157

‡ Per-share figures and share counts are adjusted for the 4-for-1 stock split (November 2022); filings made before it reported them unadjusted.

Fiscal years (TECH's year ends in late June)

In millions of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	199	173	181	152	162	265
Short-term investments	—	74	24	1	—	—
Marketable securities	32	74	—	—	—	—
Accounts receivable	145	195	218	241	207	217
Inventory	117	141	172	180	189	196
Total current assets	511	606	621	617	608	744
Property and equipment, net	208	223	226	251	246	232
Right-of-use asset	74	66	98	91	73	67
Goodwill	843	822	873	973	981	975
Total assets	2,263	2,295	2,639	2,704	2,558	2,587
Accounts payable	29	34	26	38	25	27
Accrued liabilities	15	18	15	25	26	20
Current portion of long-term debt	13	13	—	—	—	—
Total current liabilities	152	176	129	159	176	164
Lease liability, non-current	68	58	94	88	84	74
Retained earnings	1,085	1,123	1,309	1,325	1,066	1,144
Total stockholders' equity	1,563	1,702	1,967	2,069	1,919	2,108
Total liabilities and equity	2,263	2,295	2,639	2,704	2,558	2,587
Common shares outstanding (cover page)‡ millions of shares	156	157	158	159	156	157

‡ Per-share figures and share counts are adjusted for the 4-for-1 stock split (November 2022); filings made before it reported them unadjusted.

Fiscal years (TECH's year ends in late June)

In millions of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	140	272	285	168	73	—
Stock-based compensation	49	42	39	38	41	41
Depreciation and amortization	88	101	107	112	110	97
Net cash from operating activities	352	325	254	299	288	292
Purchases of property and equipment	44	45	38	63	31	29
Net cash from investing activities	(244)	(97)	(266)	(203)	(35)	(18)
Share repurchases	43	161	20	80	276	42
Dividends paid	50	50	50	50	50	50
Net cash from financing activities	(63)	(243)	23	(122)	(254)	(169)
Net change in cash	52	(27)	8	(29)	10	103

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
United Therapeutics	1,803	783	314*	42.9M	—	Q2 FY26 10-QJun 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.